Cargando…

Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer

Programmed death-1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) help tumor cells evade immune surveillance, and are regarded as important targets of anti-tumor immunotherapy. Post-translational modification of PD-L1 has potential value in immunosuppression. Here, we identified that ubiqui...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hanshen, Zhang, Xiaozhen, Lao, Mengyi, Sun, Kang, He, Lihong, Xu, Jian, Duan, Yi, Chen, Yan, Ying, Honggang, Li, Muchun, Guo, Chengxiang, Lu, Qingsong, Wang, Sicheng, Su, Wei, Liang, Tingbo, Bai, Xueli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950432/ https://www.ncbi.nlm.nih.gov/pubmed/36539510 http://dx.doi.org/10.1038/s41418-022-01102-z

Ejemplares similares

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
por: Zhang, Xiaozhen, et al.
Publicado: (2022)

Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells
por: Lao, Mengyi, et al.
Publicado: (2021)

RCAN1-mediated calcineurin inhibition as a target for cancer therapy
por: Lao, Mengyi, et al.
Publicado: (2022)

Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix
por: Duan, Yi, et al.
Publicado: (2023)

Integrative analysis identified two subtypes and a taurine-related signature to predict the prognosis and efficacy of immunotherapy in hepatocellular carcinoma
por: Lu, Qingsong, et al.
Publicado: (2023)

Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer
por: Li, Muchun, et al.
Publicado: (2022)

NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
por: Zhang, Xiaozhen, et al.
Publicado: (2021)

O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy
por: Lu, Qingsong, et al.
Publicado: (2022)

Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy
por: Ying, Honggang, et al.
Publicado: (2022)

Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation
por: Huang, Xing, et al.
Publicado: (2020)

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
por: Huang, Xing, et al.
Publicado: (2020)

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
por: Huang, Xing, et al.
Publicado: (2020)

Outcomes of liver transplantation using moderately steatotic liver from donation after cardiac death (DCD)
por: Duan, Xin, et al.
Publicado: (2020)

A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study
por: Huang, Dabing, et al.
Publicado: (2021)

Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
por: Liu, Lingyue, et al.
Publicado: (2022)

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
por: Tang, Tianyu, et al.
Publicado: (2021)

Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial
por: Ma, Tao, et al.
Publicado: (2022)

The AKT-independent MET–V-ATPase–MTOR axis suppresses liver cancer vaccination
por: Huang, Xing, et al.
Publicado: (2020)

Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application
por: Gao, Hongli, et al.
Publicado: (2023)

Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment
por: Huang, Mei-Ling, et al.
Publicado: (2022)

Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell
por: Huang, Xing, et al.
Publicado: (2021)

Substrate specificity of the ubiquitin and Ubl proteases
por: Ronau, Judith A, et al.
Publicado: (2016)

Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy
por: Huang, Xing, et al.
Publicado: (2020)

Ubiquitin-specific protease 4 is inhibited by its ubiquitin-like domain
por: Luna-Vargas, Mark P A, et al.
Publicado: (2011)

The Molecular Basis for Ubiquitin and Ubiquitin-like Specificities in Bacterial Effector Proteases
por: Pruneda, Jonathan N., et al.
Publicado: (2016)

Characterization of the Ubiquitin C-Terminal Hydrolase and Ubiquitin-Specific Protease Families in Rice (Oryza sativa)
por: Wang, Dong-Hui, et al.
Publicado: (2018)

Ddi1 is a ubiquitin-dependent protease
por: Yip, Matthew C. J., et al.
Publicado: (2020)

Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders
por: Kitamura, Hiroshi
Publicado: (2023)

Calreticulin couples with immune checkpoints in pancreatic cancer
por: Huang, Xing, et al.
Publicado: (2020)

Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity
por: Huang, Xing, et al.
Publicado: (2020)

Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy
por: Yang, Jiaqi, et al.
Publicado: (2022)

Ubiquitin-Specific Protease 2 (OsUBP2) Negatively Regulates Cell Death and Disease Resistance in Rice
por: Jiang, Ruirui, et al.
Publicado: (2022)

Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system
por: Xu, Daichao, et al.
Publicado: (2015)

Structural basis for the SUMO protease activity of the atypical ubiquitin-specific protease USPL1
por: Li, Ying, et al.
Publicado: (2022)

Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy
por: Gutic, Bojana, et al.
Publicado: (2023)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023)

Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes
por: Cruz, Lucas, et al.
Publicado: (2021)

Emerging Roles of Ubiquitin-Specific Protease 25 in Diseases
por: Zhu, Wenjing, et al.
Publicado: (2021)

Targeting ubiquitin signaling for cancer immunotherapy
por: Zhou, Xiaofei, et al.
Publicado: (2021)

To Ubiquitinate or Not to Ubiquitinate: TRIM17 in Cell Life and Death
por: Basu-Shrivastava, Meenakshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q2fmaaeomdbv5hj6tr5mgpqh16